nelfinavir has been researched along with carfilzomib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bader, J; Besse, A; Besse, L; Driessen, C; Kraus, M; Morgan, GJ; Overkleeft, HS; Rasche, L; Stolze, SC; Weinhold, N | 1 |
| Besse, A; Besse, L; Driessen, C; Kraus, M; Tarantino, I | 1 |
3 other study(ies) available for nelfinavir and carfilzomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HIV Protease Inhibitors; Humans; Lopinavir; Multiple Myeloma; Nelfinavir; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2018 |
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2023 |